Q-omics provides the consensus-scored PNRC1 profile across patient tissues and cancer cell-line models. PNRC1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PNRC1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PNRC1 RNA expression shows 18,215 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where PNRC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNRC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNRC1 survival associations across molecular data types. PNRC1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNRC1 RNA expression–survival associations across cancer types. High PNRC1 expression shows unfavorable associations in KIRP, LGG and SCLC, but favorable associations in KIRC, SKCM and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for PNRC1 RNA expression.
This table summarizes PNRC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PNRC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNRC1 shows lower tumor expression in KICH, THCA, LUAD, UCEC and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher PNRC1 RNA expression in tumor versus normal tissue (log2 FC = +0.959, t-test p < 0.001).
This table shows molecular features associated with PNRC1 in patient tissues and cancer cell lines. In patient samples, PNRC1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PNRC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SKIN.
